Ch. Pervaiz Elahi Institute of Cardiology
Multan, Punjab Province, 59341, Pakistan
NCT Number: NCT05290324
Propofol and midazolam are used frequently as sedating agents among patients who undergo coronary artery bypass graft surgery but no study in Pakistan has been done to compare their effectiveness aiming early extubation.
Looking for future studies?
Notify Me20 year–20 year
All sexes
Interventional
Not applicable
Multan, Punjab Province, 59341, Pakistan
Propofol is an intra lipid and alkali phenol chemically it is unrelated to sedative agents or anaesthetic. Midazolam is a banzodiazepen. Most of its properties are similar to diazepam. It is a common practice to use sedatives to provide comfort and decrease "ventilator-asynchrony" in critically ill patients that may require prolonged invasive mechanical ventilation. The other reason to employ sedatives is to reduce the anxiety associated with the inaviseve procedures routinely conducted in the ICU.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
Other names: Versed
Time frame: Time in minutes calculated from end of surgery to the time of awakening up to 24 hours in both study groups
Duration of post-surgery sedation following cardiac surgery
Time frame: Time taken in minutes from the end of the cardiac surgery to post-surgery extubation up to 1 week duration in both study groups
Time taken from the end of cardiac surgery to post-surgery extubation
Chaudhry Pervaiz Elahi Institute of Cardiology
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsNCT07468955
Arterial Occlusive Diseases, Arteriosclerosis
Kütahya, Center, Turkey (Türkiye)
View Trial DetailsNCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsNCT04058990
Arterial Occlusive Diseases, Arteriosclerosis
Kitakyushu, Fukuoka, Japan
View Trial Details